Business
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
– Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500 mg/dL, a threshold associated with increased risk of acute pancreatitis\n\n\n– No adjudicated acute pancreatitis events occurred in any patient receiving plozasiran during the 2-year Phase 2b Open-Label Expansion (OLE) Study\n\n\n– Favorable and durable improvements in atherogenic lipoproteins, including remnant cholesterol, non-HDL cholesterol, and ApoB, were observed, with a safety profile consistent with earlier trials\n\n\n PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of investigational plozasiran supporting its potential as therapeutic solution for a diverse spectrum of patients with hypertriglyceridemia (HTG).\n\n\nThe data were presented by Dr. Christie M. Ballantyne, MD, professor at Baylor College of Medicine, member of the Texas Heart Institute at Baylor, and Principal Investigator of the 2-year OLE study, during an oral presentation at the American College of Cardiology 75th Annual Scientific Session & Expo (ACC.26) in New Orleans and published in the American Journal of Preventive Cardiology.\n\n\n“With a new therapy, it is always important to see longer term data to better understand both efficacy and safety. In a long-term open-label extension study, plozasiran treatment was associated with dramatic and meaningful reductions in TGs. In addition, the lack of any acute pancreatitis events during two years of treatment in a patient population that includes those at high risk was particularly reassuring,” said Dr. Ballantyne. “These data reinforce the importance of APOC3 silencing as a central mechanism in promoting triglyceride clearance. The study provides promising evidence that plozasiran treatment may lead to durable, sustained reductions in triglycerides and atherogenic lipoproteins across the hypertriglyceridemia spectrum.”\n\n\nPlozasiran is designed to reduce the hepatic production of apolipoprotein C-III (APOC3) through targeted RNA interference. APOC3 is a key regulator of triglyceride metabolism that inhibits both lipoprotein lipase (LPL)-dependent and LPL-independent pathways involved in triglyceride catabol...